

Rs in lakhs (except for number of shares)

Statement of audited results for the quarter and year ended 31 March 2014						
Part I Sl No.	Particulars	3 months ended 31/03/2014 (Audited) ⁶	3 months ended 31/12/2013 (Unaudited)	3 months ended 31/03/2013 (Audited) ⁶	Year ended 31/03/2014 (Audited)	Previous year ended 31/03/2013 (Audited)
1	Income from operations					
	a) Net sales/ income from operations (net of excise duty)	11,414.94	11,887.92	9,485.13	47,374.82	39,025.42
	b) Other operating income	0.28	7.65	6.52	22.28	16.68
	Total income from operations (net)	11,415.22	11,895.58	9,491.65	47,397.10	39,042.10
2	Expenses					
	(a) Cost of materials consumed	1,435.36	1,184.17	1,454.65	6,385.87	4,497.53
	(b) Purchase of stock-in-trade	5,580.94	2,873.43	3,039.64	12,228.88	11,163.77
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,540.17)	(182.00)	(1,383.90)	(2,003.40)	(347.91)
	(d) Employee benefits expense	5,471.00	3,503.17	3,681.98	16,046.01	14,846.02
	(e) Depreciation and amortisation expense	297.34	303.07	548.36	1,012.49	1,227.82
	(f) Other expenses	2,958.17	4,219.83	4,075.66	16,037.00	15,728.17
	Total expenses	13,202.64	11,901.67	11,416.39	49,706.85	47,115.40
3	Profit/(loss) from operations before other income, finance costs and exceptional items (1-2)	(1,787.42)	(6.09)	(1,924.74)	(2,309.75)	(8,073.30)
4	Other income	141.63	157.88	67.21	920.84	1,046.29
5	Profit/(loss) from ordinary activities before finance costs and exceptional items (3+4)	(1,645.79)	151.79	(1,857.53)	(1,388.91)	(7,027.01)
6	Finance costs	-	-	-	-	-
7	Profit/(loss) from ordinary activities after finance costs but before exceptional items (5-6)	(1,645.79)	151.79	(1,857.53)	(1,388.91)	(7,027.01)
8	Exceptional items ⁴	1,388.91	-	-	1,388.91	-
9	Profit/(loss) from ordinary activities before tax (7+8)	(256.88)	151.79	(1,857.53)	-	(7,027.01)
10	Tax expense	-	-	-	50.89	1,926.23
11	Net profit/(loss) from ordinary activities after tax (9-10)	(256.88)	151.79	(1,857.53)	(50.89)	(8,953.24)
12	Extraordinary item	-	-	-	-	-
13	Net profit/(loss) for the period (11-12)	(256.88)	151.79	(1,857.53)	(50.89)	(8,953.24)
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year				16,659.50	9,475.29
16	Basic and diluted earnings (Rs) per share [not annualised]	(1.03)	0.61	(7.43)	(0.20)	(35.81)

Select information for the quarter and year ended 31 March 2014						
Part II A	Particulars of shareholding					
1	Public shareholding					
	- Number of shares	6,250,000	6,250,000	2,500,050	6,250,000	2,500,050
	- Percentage of shareholding	25.0%	25.0%	10.0002%	25.0%	10.0002%
2	Promoters and promoter group shareholding					
a)	Pledged/Encumbered					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
b)	Non-encumbered					
	- Number of shares	18,750,000	18,750,000	22,499,950	18,750,000	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	75.0%	75.0%	89.9998%	75.0%	89.9998%

B.	Particulars	3 months ended 31/03/2014
	Investor complaints	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 30 May 2014.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities (till 31 January 2014) (Also refer note 5 below).
- Other income for the year ended 31 March 2014 includes an amount of Rs 253.02 lakhs towards compensation for factory land acquired by National Highway Authority of India (NHAI) during the financial year 2011-12. In the earlier years, the Company had accrued an income of Rs 763.55 lakhs (which includes an amount of Rs 693.49 lakhs accrued during the year ended 31 March 2013) based on the information available with the Company. The aforesaid additional income has been recognised on the receipt of the total compensation during the year ended 31 March 2014. Accordingly, the Company has accounted for the capital gains tax aggregating Rs 50.89 lakhs during the year ended 31 March 2014.
- The Company had entered into a subvention agreement ("the agreement") dated 7 May 2013 with AstraZeneca Pharmaceuticals AB Sweden ("Promoter Company") wherein to assist the Company in its efforts to establish/grow its presence in the Indian market, the Promoter Company had voluntarily decided to provide a non refundable financial grant. Accordingly, the Company received Rs 2,132.20 lakhs during the quarter ended 31 March 2014, Rs 2,171.4 lakhs during the quarter ended 31 December 2013 and Rs 8,624 lakhs during the year ended 31 March 2014 as financial grant. The Promoter Company vide its letter dated 1 March 2014 informed the Board of Directors of the Company of a revision of the agreement, whereby the payment under the agreement was revised to USD 14 million (Indian rupee equivalent 8,624 lakhs) and period covered under the agreement to financial year 2013-14. The Promoter Company vide its letter dated 25 April 2014 terminated the agreement effective 25 March 2014 on the ground that the Company's business and financial performance has been in line with more recent expectations and that the Company shall not require any further grant for the financial years 2014-15 and 2015-16. Consequent to the termination of the agreement, out of the total subvention receipt amounting to Rs 8,624 lakhs during the year ended 31 March 2014, the Company has credited subvention receipt amounting to Rs 1,388.91 lakhs representing loss incurred by the Company for the year ended 31 March 2014 to the profit and loss account and the balance subvention receipt amounting to Rs 7,235.09 lakhs has been transferred by the Company to capital reserve during the quarter and year ended 31 March 2014.
- Effective 1 February 2014, AstraZeneca Group Companies has acquired the Global Diabetic business of Bristol-Myers Squibb Company. Consequent to the aforesaid acquisition, the Company has entered into a consignment sale agreement with Bristol Myers Squibb India Private Limited (BMS). Accordingly, sale of diabetic products by BMS in India for the period 1 February 2014 to 31 March 2014 has been included as part of the sales of the Company. Sales for the quarter and year ended 31 March 2014 is not comparable with sales for the respective comparative periods to the extent of these sales. The Company was earning income from co-promotion services for the period upto 31 January 2014. The Company will not earn any further income from the above mentioned co-promotion services after 31 January 2014.
- The figures for the quarter ended 31 March 2014 and the corresponding quarter ended in the previous year as reported in this financial result is the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also figures upto the third quarter of the relevant financial year were only reviewed and not subjected to audit. The statutory auditors have issued an unqualified audit report. The audit report has been filed with the stock exchange and is also available on the Company's website.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Sanjay Murdeshwar
Sanjay Murdeshwar
Managing Director

Bangalore
Dated: 30 May 2014

AstraZeneca Pharma India Limited
Regd Office : 'Avishkar' Off Bellary Road , Hebbal Bangalore - 560 024
Statement of assets and liabilities

(Rs in lakhs)			
Sl.no.	Particulars	As at 31 March 2014 (Audited)	As at 31 March 2013 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	500.00	500.00
	(b) Reserves and Surplus	16,659.50	9,475.29
	(c) Money received against share warrants	-	-
	Sub-total - Shareholders' funds	17,159.50	9,975.29
2	Share application money pending allotment	-	-
3	Non-current liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	48.94	48.94
	(d) Long-term provisions	-	-
	Sub-total - Non-current liabilities	48.94	48.94
4	Current liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	10,987.10	9,067.22
	(c) Other current liabilities	9,649.90	7,720.83
	(d) Short-term provisions	3,713.30	3,797.89
	Sub-total - Current liabilities	24,350.30	20,585.94
	TOTAL - EQUITY AND LIABILITIES	41,558.74	30,610.17
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	10,353.09	9,824.15
	(b) Non-current investments	0.05	0.57
	(c) Deferred tax assets (net)	-	-
	(d) Long-term loans and advances	3,904.85	3,472.78
	(e) Other non-current assets	37.14	831.60
	Sub-total - Non-current assets	14,295.13	14,129.10
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	9,575.76	8,536.91
	(c) Trade receivables	5,292.92	2,796.32
	(d) Cash and bank balances	8,907.09	1,846.86
	(e) Short-term loans and advances	3,033.96	2,033.21
	(f) Other current assets	453.88	1,267.77
	Sub-total - Current assets	27,263.61	16,481.07
	TOTAL - ASSETS	41,558.74	30,610.17



AstraZeneca Pharma India Limited
Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Segment wise revenue, results and capital employed

Sl.no	Particulars	3 months ended 31/03/2014 (Audited) ³	3 months ended 31/12/2013 (Unaudited)	3 months ended 31/03/2013 (Audited) ³	Year ended 31/03/2014 (Audited)	Year ended 31/3/2013 (Audited)
1	Segment revenue					
	(a) Healthcare	11,097.78	10,965.93	8,535.62	44,178.44	35,586.81
	(b) Others	317.44	929.65	956.03	3,218.66	3,455.29
	Total	11,415.22	11,895.58	9,491.65	47,397.10	39,042.10
	Less: Inter-segment revenue	-	-	-	-	-
	Net income from operations	11,415.22	11,895.58	9,491.65	47,397.10	39,042.10
2	Segment results					
	Profit/(loss) before tax and interest					
	(a) Healthcare	(1,969.08)	(147.37)	(2,089.94)	(3,113.81)	(8,477.84)
	(b) Others	181.66	141.28	165.20	804.06	404.54
	Total	(1,787.42)	(6.09)	(1,924.74)	(2,309.75)	(8,073.30)
	Add: Other income	141.63	157.88	67.21	920.84	1,046.29
	Add: Exceptional item	1,388.91	-	-	1,388.91	-
	Less: Interest	-	-	-	-	-
	Total profit/(loss) before tax	(256.88)	151.79	(1,857.53)	0.00	(7,027.01)
3	Capital employed					
	(a) Healthcare	7,829.14	7,079.94	6,929.46	7,829.14	6,929.46
	(b) Others	(559.23)	31.29	122.37	(559.23)	122.37
	(c) Unallocated	9,889.59	3,070.05	2,923.46	9,889.59	2,923.46
	Total	17,159.50	10,181.28	9,975.29	17,159.50	9,975.29

Notes :

- 1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.
- 2 Exceptional item for the quarter and year ended 31 March 2014 represents receipt under subvention agreement credited to statement of profit and loss to the extent of losses incurred during the year ended 31 March 2014.
- 3 The figures for the quarter ended 31 March 2014 and the corresponding quarter ended in the previous year as reported in this financial result is the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year.



B S R & Co. LLP

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1 Inner Ring Road
Koramangala
Bangalore 560 071 India

Telephone: + 91 80 3980 6000
Fax: + 91 80 3980 6999

To Board of Directors AstraZeneca Pharma India Limited

We have audited the accompanying Statement of Financial results ("the Statement") of AstraZeneca Pharma India Limited ("the Company") for the year ended 31 March 2014, attached herewith, being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement issued by the Securities and Exchange Board of India ("Listing Agreement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management and have not been audited by us. Attention is drawn to the fact that the figures for the quarter ended 31 March 2014 and the corresponding quarter ended in the previous year as reported in the Statement are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit.

The Statement has been prepared on the basis of the annual financial statements of the current year and reviewed quarterly financial results upto the end of the third quarter. Our responsibility is to express an opinion on the Statement based on our audit of the financial statements of the current year which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956, ("the Act") read with the General Circular 15/2013 dated 13 September 2013 of the Ministry of Corporate Affairs in respect of Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Clause 41 of the Listing Agreement.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the Statement. An audit includes assessing the accounting principles used and significant estimates made by Management. We believe that our audit provides a reasonable basis for our opinion.

Without qualifying our opinion, we draw attention to

- note 4 to the Statement for the quarter and year ended 31 March 2014 which states that the Company has entered into a subvention agreement ("the Agreement") dated 7 May 2013 with AstraZeneca Pharmaceuticals AB Sweden ("Promoter Company") wherein to assist the Company in its efforts to establish/grow its presence in the Indian market, the Promoter Company has voluntarily decided to provide a non refundable financial grant. Accordingly, the Company received Rs 2,132.20 lakhs during the quarter ended 31 March 2014, Rs 2,171.40 lakhs during the quarter ended 31 December 2013 and Rs 8,624.00 lakhs during the year ended 31 March 2014 as a financial grant. The Promoter Company vide its letter dated 1 March 2014 informed the Board of Directors of the Company regarding the revision to the agreement, whereby restricting the payment under the agreement to USD 14 million (Indian rupee equivalent 8,624 lakhs) and period covered under the agreement to financial year 2013-14. Accordingly, the Promoter Company vide letter dated 25 April 2014 has terminated the agreement effective 25 March 2014 on the grounds that the Company's business and financial performance has been inline with more recent expectations, and that the Company shall not require any further grant for the financial years

B S R & Co. (a partnership firm with
Registration No. BA61223) converted into
B S R & Co. LLP (a Limited Liability Partnership
with LLP Registration No. AAB-B1811)
with effect from October 14, 2013

Registered Office:
1st Floor, Lodha Excelus
Apollo Mills Compound
N.M. Joshi Marg, Mahalakshmi
Mumbai - 400 011

B S R & Co. LLP

2014-15 and 2015-16. Out of the total receipt of Rs 8,624 lakhs; Rs 1,388.91 lakhs representing loss incurred by the Company during the year ended 31 March 2014 has been credited to statement of profit and loss and balance Rs 7,235.09 lakhs has been transferred to capital reserve during the quarter and year ended 31 March 2014.

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- (i) is presented in accordance with the requirements of Clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net loss and other financial information of the Company for the year ended 31 March 2014.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the Management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the Company in terms of Clause 35 of the Listing Agreement and found the same to be correct.

for B S R & Co. LLP

Chartered Accountants

Firm Registration Number: 101248W



Sunil Gaggar

Partner

Membership No: 104315

Place: Bangalore

Date: 30 May 2014